The EU review of Illumina’s $8 billion takeover of cancer-testing company Grail, on the books since June 2021, could move quickly now that the bloc’s General Court has issued its long-awaited judgment confirming that the European Commission indeed has the right to vet it (see here).
Up until now, waiting for